Jove
Visualize
Contact Us

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

3
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
3
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2
Coronary Artery Disease IV: Medical Management01:26

Coronary Artery Disease IV: Medical Management

11
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
11
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

135
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
135
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

519
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
519

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention through vascular leakage reduction in white adipose tissue.

Diabetes, obesity & metabolism·2025
Same author

Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study.

European heart journal. Cardiovascular pharmacotherapy·2025
Same author

Glycemia Risk Index is Associated With Risk of Albuminuria Among Individuals With Type 1 Diabetes.

Journal of diabetes science and technology·2025
Same author

Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.

Diabetes, obesity & metabolism·2024
Same author

Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study.

European heart journal. Cardiovascular pharmacotherapy·2023
Same author

Weight-adjusted waist as an integrated index for fat, muscle and bone health in adults.

Journal of cachexia, sarcopenia and muscle·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 12, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review.

Jung A Kim1, Nam Hoon Kim1

  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Journal of Lipid and Atherosclerosis
|June 10, 2025
PubMed
Summary
This summary is machine-generated.

Lipoprotein(a) [Lp(a)] is a key driver of cardiovascular disease. This review examines Lp(a) in Asian populations, noting lower levels but persistent risk, and explores new therapies.

Keywords:
AsianAtherosclerosisCardiovascular diseasesLipoprotein(a)

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.0K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.2K

Related Experiment Videos

Last Updated: Jun 12, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.0K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.2K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Epidemiology

Background:

  • Lipoprotein(a) [Lp(a)] is a genetically determined particle causally linked to atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, and calcific aortic valve stenosis.
  • Lp(a) possesses unique atherogenic properties due to its apolipoprotein(a) [apo(a)] component, differing from low-density lipoprotein.
  • Ethnic variations in Lp(a) levels exist, with East Asians typically showing lower median concentrations due to specific LPA gene variants and apo(a) isoforms.

Purpose of the Study:

  • To review the epidemiology, genetic factors, clinical significance, and therapeutic strategies for Lp(a) in Asian populations.
  • To highlight the need for ethnicity-specific Lp(a) thresholds and further research in this demographic.
  • To discuss emerging therapies targeting Lp(a) and their relevance in Asian subgroups.

Main Methods:

  • Systematic review of observational studies and genetic analyses concerning Lp(a) in Asian populations.
  • Analysis of data on cardiovascular outcomes associated with Lp(a) levels in Asians.
  • Evaluation of current and emerging therapeutic agents for Lp(a) reduction.

Main Results:

  • Elevated Lp(a) is associated with increased ASCVD risk in Asians, despite generally lower median concentrations.
  • Observational studies link higher Lp(a) to coronary artery calcification, myocardial infarction, stroke, and recurrent cardiovascular events in Asian populations.
  • Novel therapies like PCSK9 inhibitors, inclisiran, and antisense oligonucleotides show promise in lowering Lp(a).

Conclusions:

  • Routine Lp(a) measurement may enhance cardiovascular risk stratification and guide treatment decisions in Asian populations.
  • Understanding ethnic variability in Lp(a) is crucial for effective cardiovascular disease prevention and management.
  • Further research and population-specific guidelines are needed to optimize Lp(a)-targeted therapies in Asia.